Patients with pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD) had increased rates of severe exacerbations, hospitalizations, and costs compared with patients with COPD without PH, according to a study in Respiratory Medicine.
The retrospective cohort study sought to quantify the clinical and economic burden of PH in patients with COPD vs a control cohort of patients with COPD alone, using data from the Optum Clinformatics Data Mart.
The study included patients with moderate to severe COPD who were enrolled from January 1, 2016, to June 30, 2021. All PH-COPD participants were required to have data for 6 months before and after their index date, which was defined as the first PH claim within a 6-month period. Additionally, all participants with PH-COPD had at least 1 inpatient visit with a PH diagnosis code or 2 outpatient visits with PH diagnosis codes separated by at least 30 days, on or after the point at which their moderate to severe COPD was identified.
Outcomes included COPD exacerbations, all-cause and COPD-related health care resource use (HCRU), and all-cause and COPD-related costs calculated as per patient per month (PPPM).
“
Patients with PH-COPD had higher rates of severe exacerbations, hospitalizations, and costs compared to COPD patients without PH, underscoring the need for targeted therapies to prevent and manage PH in patients with COPD.
Propensity score matching was used to select matched cohorts of patients with PH-COPD and COPD alone, with 1627 participants in each group. The mean (SD) age in both groups of 71.2 (9.6) years, and 57% were female. The mean follow-up from index diagnosis date was 18.0 (12.4) months in the PH-COPD group and 18.6 (14.0) months in the COPD group.
The PH-COPD group had a significantly greater percentage of exacerbations that occurred anytime postindex compared with the COPD group (71.2% vs 58.4%, P <.001). Participants with PH-COPD had about twice as many exacerbation-related visits PPPM occurring anytime postindex compared with participants with COPD only (mean [SD], 0.20 [0.54] vs 0.11 [0.27], P <.001). Severe exacerbations were also more common in patients with PH-COPD vs those with COPD alone (45.9% vs 26.0%, P <.001).
The 6-month postindex and anytime postindex all-cause and COPD-related HCRU PPPM estimates were greater for patients with PH-COPD vs those with COPD. A similar pattern was observed for COPD-related HCRU for all HCRU visit types, except for outpatient physician office visits. Postindex, a greater percentage of the PH-COPD group vs the COPD group had all-cause hospitalizations (59.6% vs 39.2%, P <.001).
The 6-month postindex and anytime postindex costs were greater for the PH-COPD group compared with the COPD group, and exacerbation-related costs had the same pattern for all HCRU visit types. The all-cause mean costs for the PH-COPD group were more than twice that for the COPD group for total costs ($10,026 [$29,777] vs $4904 [$19,982], P <.001) and medical costs ($9,512 [$29,820] vs $4404 [$19,972], P <.001).
A higher percentage of patients in the PH-COPD cohort than in the COPD cohort were using short-acting agonists 6 months postindex (61.3% vs 55.5%, P <.001).
Limitations include the observational database analysis design; the Optum database’s use of a standard pricing methodology and omission of exact cost estimates; and the lack of evaluation of patient use of therapies such as diuretics and supplemental oxygen to manage their conditions.
“Patients with PH-COPD had higher rates of severe exacerbations, hospitalizations, and costs compared to COPD patients without PH, underscoring the need for targeted therapies to prevent and manage PH in patients with COPD,” the investigators stated.
Disclosure: This work was supported by funding provided by United Therapeutics Corporation. Some of the study authors declared an affiliation with a biotechnology company. Please see the original reference for a full list of authors’ disclosures.

















